Stem Cell Transplantation with NiCord® for Blood Cancers

Recruiting in Palo Alto (17 mi)

+51 other locations

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Gamida Cell ltd

No Placebo Group

Pivotal Trial (Near Approval)

Prior Safety Data

Trial Summary

What is the purpose of this trial?

This study is an open-label, controlled, multicenter, international, Phase III, randomized study of transplantation of NiCord® versus transplantation of one or two unmanipulated, unrelated cord blood units in patients with acute lymphoblastic leukemia or acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia or lymphoma, all with required disease features rendering them eligible for allogeneic transplantation.

Eligibility Criteria

This trial is for patients with certain blood cancers like leukemia or lymphoma who need a stem cell transplant and don't have a fully matched donor. They should be in good enough health to undergo the procedure, not pregnant, without active infections or other cancers, and have a back-up stem cell source.

Inclusion Criteria

I have a backup source for stem cells.

My condition meets the specific disease criteria for the trial.

Signed written informed consent

See 3 more

Exclusion Criteria

I have had a stem cell transplant from a donor.

Pregnancy or lactation

I have a donor who is a perfect match for me.

See 3 more

Treatment Details

Interventions

Cord Blood Unit (Stem Cell Transplantation)
NiCord® (Omidubicel) (Stem Cell Transplantation)

Trial OverviewThe study compares NiCord® (omidubicel), an advanced cord blood unit, with standard unmanipulated cord blood units for stem cell transplantation in patients with specific types of leukemia and lymphoma.

Participant Groups

2Treatment groups

Experimental Treatment

Active Control

Group I: NiCord® (omidubicel)Experimental Treatment1 Intervention

NiCord® is a cryopreserved stem/progenitor cell based product comprised of: 1. ex vivo expanded, umbilical cord blood-derived hematopoietic CD34+ progenitor cells (NiCord® cultured fraction (CF)) 2. the non-cultured cell fraction of the same Cord Blood Unit (CBU) (NiCord® Non-cultured Fraction (NF)) consisting of mature myeloid and lymphoid cells. Both fractions, i.e. NiCord® CF and NiCord® NF, will be kept frozen until they are thawed and infused on the day of transplantation.

Group II: Unmanipulated CBU(s)Active Control1 Intervention